ArticleScientific reports2025
A theoretical model for detecting drug interaction with awareness of timing of exposure.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Potential Drug Dose-Specific Adverse Three-Drug Combinations: A US Insurance Claims Data-Based Study.Pharmacoepidemiology and drug safety · 2025Article
- A trajectory-informed model for detecting drug-drug-host interaction from real-world data.Journal of biomedical informatics · 2025Article
- Mapping the Global Research on Drug-Drug Interactions: A Multidecadal Evolution Through AI-Driven Terminology Standardization.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Drug-drug interaction-induced (DDI-induced) adverse drug event (ADE) is a significant public health burden. Risk of ADE can be related to timing of exposure (TOE) such as initiating two drugs concurrently or adding one drug to an existing drug. Thus, real-world data based DDI detection shall be expanded to investigate precise adverse DDI with a special awareness on TOE. We developed a Sensitive and Timing-awarE Model (STEM), which was able to optimize the probability of detection and control false positive rate for mining all two-drug combinations under case-crossover design, in particular for DDIs with TOE-dependent risk. We analyzed a large-scale US administrative claims data and conducted performance evaluation analyses. We identified signals of DDIs by using STEM, in particular for DDIs with TOE-dependent risk. We also observed that STEM identified significantly more signals than the conditional logistic regression model-based (CLRM-based) methods and the Benjamini-Hochberg procedure. In the performance evaluation, we found that STEM demonstrated proper false positive control and achieved a higher probability of detection compared to CLRM-based methods and the Benjamini-Hochberg procedure. STEM has a high probability to identify signals of DDIs in high-throughput DDI mining while controlling false positive rate, in particular for detecting signals of DDI with TOE-dependent risk.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.